GALAXY

Gut-and-Liver Axis in Alcoholic Liver Fibrosis

What is GALAXY?

GALAXY is a H2020 project that aims to optimize personalized healthcare for patients with liver disease,

by stratifying individuals who would benefit from targeted healthcare efforts versus those who would not,

and thus to reduce the economic burden for health care systems and to improve health outcome for the patients.

GALAXY has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668031

Latest News

03.12.2021

Costs and benefits of targeting alcohol-related liver disease

Online GALAXY seminar 24 February 3-4.30 pm (CET)

Read article

24.09.2021

GALAXY researcher receives Novozymes prize

Peer Bork has received the Novozymes Prize 2021 in recognition of the outstanding research he has undertaken during his entire research career. The Prize is accompanied by DKK 5 million and is awarded by the Novo Nordisk Foundation.

Read article

23.09.2021

New GALAXY publication: Increasingly dysbalanced collagen turnover as fibrosis stage worsen

Maja Thiele on Center for Liver Research's new GALAXY-publication about upregulation of fibrillar collagen formation (PRO-C3) and degradation (C3M) in alcohol-related liver disease.

Read article

24.08.2021

Last patient – last visit in GALAXY RCT

In August, a very important milestone was reached in the RCT SYN-ALD, when the last patient completed the last visit.

Read article

08.04.2021

Hepatology for Dummies

7 April, the first Academy Afternoon in the GALAXY and MicrobLiver consortia was hosted by Odense University Hospital.

Read article

16.03.2021

PhD defence Ditlev Nytoft Rasmussen

26 March, Ditlev Nytoft Rasmussen will defend his PhD on prognostic markers in alcohol-related liver disease.

Read article

11.03.2021

GALAXY online meeting

1-3 March, GALAXY hosted a 3 days online meeting for all partners together with project MicrobLiver

Read article

25.01.2021

Multinational collaboration establish common cut-offs for liver stiffness measurements

Finally, researchers have agreed on the interpretation of liver stiffness measurements. There has long been disagreement about which cut-off values to use for transient elastography (FibroScan). With the use of GALAXY data, a multinational collaboration has now established cut-off values to rule in and rule out compensated advanced chronic liver disease across the four major liver disease etiologies.

Read article

Inclusion of patients

20.01.2021

Inclusion of patients concluded in the fourth GALAXY study

55 patients with alcoholic liver disease are now included in the SYN-ALD a randomized controlled trial in GALAXY.

Read article

04.12.2020

GALAXY part of multi-centre study published in AP&T

New study shows that digital assistance improves physician’s accuracy to predict who will develop complication to cirrhosis and die from alcohol-related liver disease.

Read article

GALAXY publications

03.09.2020